Artrya’s Sonic Contract Signals Growth but Revenue Depends on Scan Uptake

• Three-year SaaS contract with Sonic Healthcare Australia
• Salix platform to be integrated into 125+ radiology centres performing CCTA scans
• Initial revenue expected in Q4 FY25, with revenue dependent on scan volumes
• Sonic Healthcare is Australia's second-largest radiology provider
• Contract supports improved coronary artery disease diagnosis and workflow efficiency

Artrya Secures Strategic Partnership with Sonic Healthcare

Artrya Limited (ASX: AYA), a Perth-based medical technology company specialising in AI-powered coronary artery disease diagnostics, announced a significant commercial contract with Sonic Healthcare Australia - Radiology. The three-year Software-as-a-Service (SaaS) agreement will see Artrya’s Salix® Coronary Anatomy platform integrated into Sonic’s extensive network of over 125 radiology centres across Australia.

This partnership represents a major milestone for Artrya, positioning its patented AI technology within one of the country’s largest diagnostic imaging providers. Sonic Healthcare, known globally for its comprehensive healthcare services, operates a vast network of radiologists and medical scientists, making it an ideal launchpad for Artrya’s platform.

Enhancing Coronary Artery Disease Diagnosis at the Point of Care

Salix is designed to improve the accuracy and efficiency of coronary artery disease assessments by analysing Coronary Computed Tomography Angiography (CCTA) scans. The AI-driven platform detects critical markers such as stenoses and high-risk plaques, providing rapid, evidence-based insights that support clinicians in diagnosing the world’s leading cause of death.

Dr Julian Adler, CEO of Sonic Healthcare Australia - Radiology, highlighted the clinical benefits: "Salix offers a personalised approach to cardiovascular imaging, enhancing diagnostic workflows and supporting our specialists to deliver improved patient care." This integration is expected to streamline the diagnostic process, enabling faster and more reliable detection of coronary vascular disease.

Commercial and Financial Implications

The contract will generate revenue for Artrya through a SaaS subscription model, with initial invoicing set to begin following system integration and user acceptance testing. While the revenue impact is currently not considered material, due to dependency on scan volumes and adoption rates, the Australian market serves as a valuable testing ground for Artrya’s technology and clinical validation.

CEO Mathew Regan expressed optimism about the deal’s strategic value: "Partnering with Sonic Healthcare places our lifesaving AI technology in the hands of clinicians nationwide, accelerating our commercial growth and supporting better outcomes for patients at risk of heart disease."

Looking Ahead

As Artrya moves toward initial revenue recognition in Q4 FY25, the focus will be on successful integration and uptake within Sonic’s radiology centres. The partnership not only validates Artrya’s technology but also sets the stage for further expansion, potentially including regulatory approvals and market entry in other regions.

With coronary artery disease remaining a critical global health challenge, the collaboration underscores the growing role of AI in transforming diagnostic medicine and improving patient care pathways.

Bottom Line?

Artrya’s deal with Sonic Healthcare marks a key commercial breakthrough, but the real test lies in adoption and scaling across Australia’s radiology network.

Questions in the middle?

• How quickly will Sonic Healthcare integrate and scale Salix across its radiology centres?
• What is the expected uptake rate of Salix among clinicians performing CCTA scans?
• Could this partnership pave the way for Artrya’s expansion into international markets?